Your browser is no longer supported. Please, upgrade your browser.
Settings
BGNE BeiGene, Ltd. daily Stock Chart
BGNE [NASD]
BeiGene, Ltd.
Index- P/E- EPS (ttm)-4.14 Insider Own0.60% Shs Outstand41.61M Perf Week-0.45%
Market Cap1.56B Forward P/E- EPS next Y-4.37 Insider Trans-64.08% Shs Float17.56M Perf Month2.29%
Income-147.80M PEG- EPS next Q-1.23 Inst Own45.10% Short Float7.73% Perf Quarter-5.42%
Sales0.40M P/S3906.14 EPS this Y-111.90% Inst Trans6.14% Short Ratio13.14 Perf Half Y14.83%
Book/sh7.76 P/B4.84 EPS next Y12.60% ROA-46.60% Target Price45.75 Perf Year39.49%
Cash/sh7.87 P/C4.77 EPS next 5Y- ROE-55.30% 52W Range24.53 - 42.09 Perf YTD23.68%
Dividend- P/FCF- EPS past 5Y- ROI-31.60% 52W High-11.69% Beta-
Dividend %- Quick Ratio6.70 Sales past 5Y- Gross Margin- 52W Low51.53% ATR1.50
Employees321 Current Ratio6.70 Sales Q/Q- Oper. Margin- RSI (14)45.07 Volatility4.23% 4.25%
OptionableNo Debt/Eq0.06 EPS Q/Q-82.50% Profit Margin- Rel Volume0.26 Prev Close37.55
ShortableYes LT Debt/Eq0.06 EarningsMay 10 Payout- Avg Volume103.24K Price37.17
Recom1.80 SMA20-4.28% SMA50-2.44% SMA2009.97% Volume12,220 Change-1.01%
Sep-22-16Initiated Maxim Group Buy $41
Feb-29-16Initiated Robert W. Baird Outperform $44
Feb-29-16Initiated Morgan Stanley Overweight
Feb-29-16Initiated Goldman Buy $33
May-17-17 04:15PM  BeiGene to Present at the 2017 UBS Global Healthcare Conference GlobeNewswire
May-10-17 04:15PM  BeiGene Reports First Quarter 2017 Financial Results GlobeNewswire
Apr-26-17 03:08PM  ETFs with exposure to BeiGene Ltd. : April 26, 2017 Capital Cube
Apr-21-17 07:00AM  BeiGene Announces Presentation on a Phase I Study of PD-1 Antibody BGB-A317 in Combination with PARP Inhibitor BGB-290 at the 2017 American Society of Clinical Oncology Annual Meeting GlobeNewswire
07:00AM  BeiGene Announces Initiation of First Pivotal Study in China of PD-1 Antibody BGB-A317 GlobeNewswire
Apr-03-17 09:26AM  BEIGENE, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Apr-02-17 01:16PM  BeiGene Presents Phase IB Data on RAF Dimer Inhibitor BGB-283 at the 2017 American Association for Cancer Research Annual Meeting GlobeNewswire
Mar-31-17 08:15AM  Blog Coverage Agenus Announced Restructuring of Business Accesswire
Mar-28-17 01:04PM  BEIGENE, LTD. Financials
Mar-24-17 10:16AM  BeiGene Ltd. :BGNE-US: Earnings Analysis: 2016 By the Numbers : March 24, 2017 Capital Cube
10:16AM  BeiGene Ltd. :BGNE-US: Earnings Analysis: 2016 By the Numbers : March 24, 2017
Mar-22-17 04:32PM  BEIGENE, LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:15PM  BeiGene Reports Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
Mar-09-17 04:22PM  BEIGENE, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:15PM  BeiGene Announces Initiation of Pivotal Study in China with BTK Inhibitor BGB-3111 in Patients with Relapsed or Refractory CLL/SLL GlobeNewswire
Mar-07-17 07:21AM  BEIGENE, LTD. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligati
07:00AM  BeiGene and Guangzhou Development District Establish Joint Venture to Build Biologics Manufacturing Facility GlobeNewswire
Mar-02-17 09:00AM  BeiGene Announces Presentation of Phase IB Data on BGB-283 at the 2017 American Association for Cancer Research Annual Meeting GlobeNewswire
09:00AM  BeiGene Announces Initiation of First Pivotal Study in China with BTK Inhibitor BGB-3111 GlobeNewswire
Feb-27-17 04:15PM  BeiGene to Present at the Cowen and Company 37th Annual Health Care Conference GlobeNewswire
Feb-08-17 04:15PM  BeiGene to Participate in the LEERINK Partners 6th Annual Global Healthcare Conference GlobeNewswire
Jan-26-17 11:11AM  Beigene Ltd (ADR) (BGNE): Heres Our Take at Insider Monkey
Jan-25-17 10:07AM  BEIGENE, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits +8.24%
08:00AM  BeiGene Initiates Global Phase III Trial of the BTK Inhibitor BGB-3111 in Waldenströms Macroglobulinemia GlobeNewswire
Dec-30-16 09:00AM  BeiGene Announces First Patient Dosing in China Phase I Trial with Investigational Anti-PD-1 Monoclonal Antibody BGB-A317 GlobeNewswire
Dec-21-16 04:15PM  BeiGene Announces First Patient Dosing in China with Investigational PARP Inhibitor BGB-290 GlobeNewswire
Dec-16-16 07:53AM  Do Hedge Funds Love Nobilis Health Corp (USA) (HLTH)? at Insider Monkey
Dec-14-16 07:16AM  Should You Add Hawaiian Telcom HoldCo Inc (HCOM) to Your Portfolio? at Insider Monkey
06:12AM  Is Federated National Holding Co (FNHC) A Good Stock To Buy? at Insider Monkey
Dec-12-16 09:09AM  BeiGene (BGNE): Strong Industry, Solid Earnings Estimate Revisions +5.18%
Dec-09-16 01:06PM  Should You Buy Beigene Ltd (ADR) (BGNE)? at Insider Monkey
Dec-07-16 07:54AM  Cancer Genetics, Inc. Is Selected by BeiGene, Ltd. to Collaborate on Clinical Trial Services & Advance Portfolio of Novel Oncology Therapeutics GlobeNewswire
Dec-06-16 06:04AM  BEIGENE, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Dec-05-16 10:00PM  BeiGene Presents Updated Clinical Data on BTK Inhibitor BGB-3111 in Patients with Waldenströms Macroglobulinemia at the 2016 American Society of Hematology Annual Meeting GlobeNewswire -8.26%
11:15AM  BeiGene Presents Updated Clinical Data on BTK Inhibitor BGB-3111 in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia at the 2016 American Society of Hematology Annual Meeting GlobeNewswire
Dec-01-16 06:11AM  [$$] Three Biotechs With Bullish Insider Buying at Barrons.com
Nov-23-16 04:25PM  BeiGene Announces Closing of $200 Million Public Offering GlobeNewswire
02:15PM  5 Stocks Insiders Love Right Now
Nov-17-16 07:27PM  BeiGene Announces Pricing of $200 Million Public Offering GlobeNewswire -11.38%
10:40AM  BeiGene Prices Secondary Offering
06:26AM  BEIGENE, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Nov-16-16 05:59PM  BeiGene Announces Proposed Public Offering GlobeNewswire
Nov-14-16 06:17AM  BEIGENE, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits +8.85%
Nov-11-16 07:00AM  BeiGene Presents Updated Clinical Data on PD-1 Antibody BGB-A317 in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer 31st Annual Meeting GlobeNewswire -10.36%
06:26AM  BeiGene reports 3Q loss
Nov-10-16 11:15AM  Beigene Files for Secondary Offering +6.27%
08:59AM  BEIGENE, LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
08:50AM  BeiGene Reports Third Quarter 2016 Financial Results GlobeNewswire
Nov-03-16 09:00AM  BeiGene Announces Oral Presentations on BTK Inhibitor BGB-3111 at the 2016 American Society of Hematology Annual Meeting GlobeNewswire -5.38%
Nov-01-16 04:15PM  BeiGene to Participate in 25th Annual Credit Suisse Healthcare Conference GlobeNewswire
Oct-10-16 10:11AM  Worst Performing Biotech IPOs of 2016 at Investopedia
Oct-07-16 05:30PM  AbbVie and JNJ, BeiGene Presents First Clinical Data for New Cancer Treatment
11:00AM  BeiGene Ltd Conference Call on BGB-3111 Data Presentation at IWWM-9 scheduled for 11:00 am ET today
09:52AM  BEIGENE, LTD. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
09:45AM  BeiGene Presents Updated Clinical Data on BTK Inhibitor BGB-3111 in Patients with Waldenstroms Macroglobulinemia at 9th International Workshop on Waldenstroms Macroglobulinemia GlobeNewswire
Oct-06-16 06:08AM  Procter & Gamble and 6 Other Stocks Spiking on Big Volume
Oct-04-16 04:15PM  BeiGene to Host Conference Call on BGB-3111 Data Presentation at IWWM-9 GlobeNewswire
Oct-03-16 04:15PM  BeiGene Appoints Ross Pettit as Senior Vice President, Global Development Operations GlobeNewswire
Sep-22-16 05:45AM  Coverage initiated on BeiGene by Maxim Group
Sep-15-16 08:25AM  BeiGene (BGNE) Catches Eye: Stock Adds 6% in Session
Sep-11-16 07:00PM  BeiGene Receives Approval to Initiate Clinical Trials in China with PD-1 Antibody BGB-A317 GlobeNewswire
Sep-06-16 04:15PM  BeiGene Appoints Jane Huang, M.D. as Chief Medical Officer, Hematology GlobeNewswire
Sep-02-16 02:26PM  These 5 Stocks Are Poised for Big Breakouts
Aug-31-16 04:15PM  BeiGene to Participate in Baird and Morgan Stanley Global Healthcare Conferences GlobeNewswire
Aug-24-16 04:15PM  BeiGene Appoints Amy Peterson, M.D. as Chief Medical Officer, Immuno-oncology GlobeNewswire
Aug-18-16 08:00AM  BeiGene Receives Approval to Initiate Clinical Trials in China with PARP Inhibitor BGB-290 GlobeNewswire
Aug-10-16 04:34PM  BEIGENE, LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:15PM  BeiGene Reports Second Quarter 2016 Financial Results GlobeNewswire
Jul-05-16 04:30PM  BeiGene Announces First Patient Dosing for Investigational BTK Inhibitor BGB-3111 in China GlobeNewswire
Jun-29-16 04:36PM  BeiGene Announces Initiation of a Combination Trial of the BTK Inhibitor BGB-3111 with the PD-1 Antibody BGB-A317 GlobeNewswire
Jun-14-16 04:44PM  U.S. regulator says too many drugmakers chasing same cancer strategy
Jun-10-16 07:00AM  U.S. regulator says too many drugmakers chasing same cancer strategy
Jun-06-16 08:07AM  BEIGENE, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:00AM  BeiGene to Participate in Goldman Sachs 37th Annual Global Healthcare Conference GlobeNewswire
Jun-05-16 09:00AM  BeiGene Presents Initial Clinical Data on PD-1 Antibody BGB-A317 at the 2016 American Society of Clinical Oncology Annual Meeting GlobeNewswire
May-26-16 09:34AM  Hedge Funds Favorite Recently-Public Companies amid Atrophied IPO Market at Insider Monkey
May-24-16 10:53AM  Biotech-Focused VHCP Managements Bullish Moves and New Picks at Insider Monkey
May-19-16 06:00AM  BeiGene Announces Presentation on BGB-A317 at the 2016 American Society of Clinical Oncology Annual Meeting GlobeNewswire
May-12-16 04:25PM  BEIGENE, LTD. Files SEC form 10-Q, Quarterly Report
May-11-16 04:23PM  BEIGENE, LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:15PM  BeiGene Reports First Quarter 2016 Financial Results GlobeNewswire
May-04-16 05:40PM  BEIGENE, LTD. Files SEC form 8-K, Change in Directors or Principal Officers
05:25PM  BeiGene Appoints Dr. Ji Li as Executive Vice President, Global Head of Business Development GlobeNewswire
Apr-21-16 09:30AM  Opening Bell, April 21, 2016
Apr-20-16 10:00AM  BeiGene (Nasdaq: BGNE) to Ring The Nasdaq Stock Market Opening Bell GlobeNewswire
Apr-19-16 09:26AM  BeiGene Ltd. :BGNE-US: Earnings Analysis: 2015 By the Numbers
Apr-18-16 07:40AM  BEIGENE, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Apr-17-16 05:15PM  BeiGene Presents Clinical Data for RAF Dimer Inhibitor BGB-283 at the 2016 American Association for Cancer Research Annual Meeting GlobeNewswire
Apr-11-16 05:10PM  BEIGENE, LTD. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligati
05:00PM  BeiGene Appoints Eric Hedrick, M.D. as Interim Chief Medical Officer GlobeNewswire
Mar-30-16 04:24PM  BEIGENE, LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  BeiGene Reports Fourth Quarter and Full Year 2015 Financial Results GlobeNewswire
Mar-29-16 04:17PM  BEIGENE, LTD. Files SEC form 8-K, Change in Directors or Principal Officers
Mar-16-16 05:48PM  BeiGene Announces Presentations on BGB-283 and Other Pipeline Agents at the 2016 American Association for Cancer Research Annual Meeting GlobeNewswire
Mar-09-16 04:39PM  The Hottest IPO of 2016 Is Crashing at Fortune
Mar-07-16 08:00AM  BeiGene Receives Approval to Initiate Clinical Trials in China With BGB-3111 GlobeNewswire -7.97%
Mar-01-16 08:00AM  BeiGene to Present at Cowen and Company 36th Annual Health Care Conference GlobeNewswire
Feb-29-16 02:25PM  Street Talk: CLR, HLT, BGNE, NFX & FET
Feb-22-16 04:04PM  13D Filing: Baker Bros. Advisors and Beigene, Ltd. (BGNE) at Insider Monkey
12:03PM  13D Filing: Billionaire Lei Zhangs Hillhouse Capital Management Reports Stake in Beigene, Ltd. (BGNE) at Insider Monkey
Chinese biotech developing cancer therapies for China and global markets.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wang XiaodongDirectorMay 04Sale41.014,491184,17160,539May 05 05:50 PM
Wang XiaodongDirectorMay 03Sale40.719,970405,87165,030May 05 05:50 PM
OYLER JOHNChief Executive OfficerMay 01Sale42.022,10088,243145,340May 01 07:44 PM
OYLER JOHNChief Executive OfficerApr 27Sale40.3734,0491,374,565147,440May 01 07:44 PM
Wang XiaodongDirectorApr 05Sale36.8311,650429,08575,000Apr 07 05:10 PM
Wang XiaodongDirectorMar 24Sale36.6018,787687,63486,650Mar 24 06:57 PM
Wang XiaodongDirectorMar 23Sale37.0011,041408,462105,437Mar 24 06:57 PM
Wang XiaodongDirectorMar 22Sale37.758,279312,517116,478Mar 24 06:57 PM
OYLER JOHNChief Executive OfficerMar 20Sale40.0213,234529,611181,489Mar 20 07:06 PM
OYLER JOHNChief Executive OfficerMar 17Sale40.022,717108,737194,723Mar 20 07:06 PM
OYLER JOHNChief Executive OfficerMar 16Sale38.7716,038621,725197,440Mar 20 07:06 PM
Wang XiaodongDirectorMar 10Sale39.947,304291,702124,757Mar 10 07:16 PM
Wang XiaodongDirectorMar 09Sale39.9518,596742,843132,061Mar 10 07:16 PM
Wang XiaodongDirectorMar 08Sale39.7810,992437,211150,657Mar 10 07:16 PM
OYLER JOHNChief Executive OfficerMar 06Sale40.2319,816797,258213,478Mar 06 07:00 PM
OYLER JOHNChief Executive OfficerMar 03Sale40.8340,0911,636,968233,294Mar 06 07:00 PM
OYLER JOHNChief Executive OfficerMar 02Sale41.2549,0922,025,104273,385Mar 06 07:00 PM
Wang XiaodongDirectorFeb 27Sale38.104,444169,328161,649Feb 27 09:11 PM
Wang XiaodongDirectorFeb 24Sale38.1428,4021,083,114166,093Feb 27 09:11 PM
Wang XiaodongDirectorFeb 23Sale38.575,505212,351194,495Feb 27 09:11 PM
OYLER JOHNChief Executive OfficerFeb 21Sale39.9810,359414,162322,477Feb 21 07:23 PM
OYLER JOHNChief Executive OfficerFeb 17Sale40.677,204292,981332,836Feb 21 07:23 PM
OYLER JOHNChief Executive OfficerFeb 16Sale40.6547,4001,926,867340,040Feb 21 07:23 PM
Malley ThomasDirectorNov 23Buy32.0030,000960,00030,000Nov 28 04:02 PM
Wang XiaodongDirectorNov 23Sale32.0093,7503,000,0000Nov 28 04:04 PM
BAKER BROS. ADVISORS LPDirectorNov 18Buy32.001,760,49556,335,8403,317,977Nov 21 06:13 PM